IND-enabling respiratory studies are an important part of the preclinical drug development process for new respiratory therapeutics. Before a potential treatment can progress into human clinical trials, pharmaceutical and biotechnology companies need appropriate preclinical evidence demonstrating that the candidate has a suitable pharmacological profile, potential therapeutic activity and an acceptable safety profile.

For respiratory drug development, IND-enabling studies can involve several interconnected areas of research, including respiratory pharmacology, respiratory disease models, pharmacokinetics, pharmacodynamics, respiratory toxicology and biomarker assessment.

The exact studies required depend on the drug candidate, mechanism of action, intended route of administration, target indication and overall development programme. However, well-designed preclinical respiratory research can provide critical information for determining whether a candidate is ready to progress towards clinical development.

What Are IND-Enabling Studies?

IND stands for Investigational New Drug. An IND application is submitted to a regulatory authority to support the initiation of clinical studies in humans.

IND-enabling studies are therefore the body of nonclinical evidence generated to support the transition from laboratory and preclinical development into human clinical research.

For respiratory drug development, this may include evidence generated through:

Respiratory pharmacology studies
In vitro respiratory research
In vivo respiratory studies
Respiratory disease models
Pharmacokinetic studies
Pharmacodynamic studies
Dose-response studies
Respiratory toxicology
Safety pharmacology
Biomarker studies
Exposure-response analysis
Translational respiratory research

The purpose is not simply to demonstrate that a drug candidate produces an effect in an animal model. Instead, IND-enabling respiratory research should help establish a coherent understanding of efficacy, mechanism, exposure, pharmacology and safety.

Why Are IND-Enabling Respiratory Studies Important?

Respiratory diseases can involve highly complex biological mechanisms. Airway inflammation, immune responses, structural changes, mucus production, airway hyperresponsiveness and pulmonary function can all contribute to disease.

This complexity makes appropriate preclinical respiratory models particularly important.

A respiratory drug candidate may demonstrate activity against a specific molecular target in vitro but still fail to produce a meaningful therapeutic response in vivo. Conversely, an in vivo response may require careful interpretation to determine whether it is associated with the intended mechanism of action.

IND-enabling respiratory studies can help answer important development questions such as:

Does the candidate demonstrate pharmacological activity?
Does the compound reach the relevant respiratory tissues?
What dose produces the desired biological effect?
Is there a relationship between exposure and pharmacological response?
Which biomarkers can demonstrate target engagement?
Does the candidate modify relevant disease pathways?
Are there potential safety concerns?
Which findings are likely to translate into clinical development?

These questions become increasingly important as a respiratory drug programme progresses towards human trials.

Respiratory Pharmacology in IND-Enabling Studies

Respiratory pharmacology examines how a drug candidate interacts with biological systems relevant to respiratory disease.

Depending on the therapeutic target, respiratory pharmacology studies may investigate effects on:

Airway inflammation
Airway smooth muscle
Bronchoconstriction
Airway hyperresponsiveness
Immune cell activity
Cytokine signalling
Mucus production
Pulmonary inflammation
Fibrotic pathways
Lung injury
Respiratory infection
Airway remodelling

Pharmacology studies can be used to establish whether a candidate produces a biological response consistent with its proposed mechanism.

For example, a candidate being developed for asthma may be evaluated using models that assess airway inflammation or airway hyperresponsiveness. A candidate targeting pulmonary fibrosis may instead require models focused on fibrotic changes and associated biomarkers.

This means that IND-enabling respiratory studies need to be designed around the specific mechanism and intended clinical indication rather than relying on a single generic respiratory model.

Respiratory Disease Models

Disease models are a major component of respiratory preclinical research.

Different respiratory diseases require different experimental approaches. Common areas of respiratory drug development include:

Asthma

Asthma research may investigate airway inflammation, airway hyperresponsiveness, immune responses and structural changes within the airways.

Preclinical asthma models can therefore be used to assess whether a drug candidate modifies relevant pathological pathways.

COPD

COPD drug development can involve models designed to investigate chronic inflammation, airway changes, emphysema-related pathology and other features associated with the disease.

Pulmonary Fibrosis

Pulmonary fibrosis research requires models capable of investigating abnormal tissue remodelling and fibrotic processes within the lung.

Acute Lung Injury and ARDS

Acute lung injury models can be used to investigate pulmonary inflammation, tissue injury and other mechanisms associated with severe acute respiratory disease.

Viral Respiratory Disease

Respiratory virus research may involve challenge models designed to investigate viral replication, host responses, pulmonary inflammation and potential antiviral activity.

The selection of an appropriate model is therefore a fundamental part of respiratory drug development.

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic and pharmacodynamic data are particularly important when progressing a respiratory drug candidate towards clinical development.

Pharmacokinetics (PK) examines what happens to a drug within the body, including aspects such as absorption, distribution, metabolism and elimination.

Pharmacodynamics (PD) examines the biological effects produced by the drug.

Together, PK and PD studies can help establish the relationship between:

Dose → Exposure → Target engagement → Biological response

This information can be valuable when selecting doses for subsequent development.

For respiratory therapeutics, understanding exposure at relevant tissues can also be particularly important. A drug intended to act within the lungs may have a different development strategy from a systemic therapy, particularly where inhaled or other pulmonary delivery approaches are being investigated.

Inhaled Drug Development

Inhaled therapies introduce additional considerations into respiratory drug development.

The intended site of action may be the respiratory tract itself, meaning researchers need to understand how administration influences pulmonary exposure and pharmacological activity.

Preclinical respiratory studies may therefore investigate factors including:

Pulmonary drug delivery
Local respiratory exposure
Systemic exposure
Dose-response relationships
Pharmacodynamic effects
Respiratory biomarkers
Lung tissue distribution
Tolerability
Potential respiratory toxicity

These studies can contribute to the overall translational strategy for an inhaled respiratory therapeutic.

Respiratory Toxicology and Safety

Safety assessment is another important part of the preclinical drug development process.

Respiratory toxicology can be particularly relevant for compounds intended to act directly within the lungs or airways.

Depending on the development programme, researchers may investigate potential effects on:

Lung tissue
Airways
Respiratory function
Inflammatory responses
Other organ systems
Local tolerability
Systemic safety

The appropriate toxicology programme depends on the candidate and the regulatory requirements applicable to the development programme.

Importantly, efficacy alone is not sufficient to progress a respiratory drug candidate. A successful preclinical programme needs to consider both therapeutic potential and safety.

Biomarkers in IND-Enabling Respiratory Research

Respiratory biomarkers can provide additional evidence about how a drug candidate is working.

Biomarkers may be used to investigate:

Target engagement
Inflammatory pathways
Disease activity
Pharmacodynamic response
Treatment response
Biological mechanism
Translational relevance

For example, changes in inflammatory biomarkers may provide evidence that a candidate is affecting a pathway associated with respiratory disease.

Combining biomarkers with functional and pathological endpoints can provide a more comprehensive understanding of drug activity.

This is particularly valuable in translational respiratory research, where the objective is to connect findings from preclinical models with potential measurements that can ultimately be investigated in human clinical studies.

Dose Selection in Respiratory Drug Development

Determining an appropriate dose is a critical part of preclinical drug development.

Dose-response studies can help researchers understand whether increasing exposure produces a corresponding change in pharmacological activity.

However, the highest dose is not necessarily the most useful dose. Understanding the relationship between exposure and response can be more informative for development decisions.

Preclinical respiratory studies may therefore investigate multiple dose levels to establish:

Minimum effective exposure
Dose-response relationships
Pharmacodynamic effects
Duration of activity
Exposure margins
Potential tolerability limitations

This information can help inform subsequent development and clinical study planning.

Translational Respiratory Research

One of the key challenges in respiratory drug development is translating findings from preclinical models into human disease.

A strong translational respiratory research programme considers this issue from an early stage.

This can involve selecting disease models with relevant biological characteristics, using appropriate respiratory biomarkers and measuring pharmacological endpoints that can potentially be connected with clinical outcomes.

Translational research can therefore help bridge the gap between:

Discovery → Preclinical research → IND-enabling studies → Clinical development

Rather than treating each stage as an isolated experiment, the overall programme can be designed around a consistent scientific hypothesis.

Choosing a Respiratory CRO for IND-Enabling Studies

Pharmaceutical and biotechnology companies may choose to work with a specialist respiratory CRO when they require external expertise or additional research capacity.

When evaluating a respiratory CRO, it can be useful to consider its experience with:

Respiratory disease models
In vivo respiratory studies
Respiratory pharmacology
Respiratory toxicology
Biomarker analysis
Pharmacokinetic and pharmacodynamic studies
Translational respiratory research
Inhaled drug development
Viral respiratory disease research
Preclinical efficacy testing

Specialist respiratory research capabilities can be particularly valuable when a development programme requires disease-specific expertise rather than a general preclinical testing approach.

Building an Effective IND-Enabling Respiratory Programme

IND-enabling respiratory studies should form part of a broader development strategy.

A typical programme may progress through several stages:

1. Target and Mechanism Research

The biological target and proposed mechanism are investigated using appropriate laboratory approaches.

2. Respiratory Drug Discovery

Potential compounds or therapeutic approaches are identified and characterised.

3. Preclinical Respiratory Research

Candidates are assessed using appropriate respiratory pharmacology and disease models.

4. Proof of Concept

The programme seeks evidence that the candidate can produce a meaningful biological or therapeutic response.

5. Pharmacology and PK/PD

Dose-response, exposure and pharmacodynamic relationships are investigated.

6. IND-Enabling Studies

The necessary nonclinical studies are conducted to support progression towards clinical development.

7. Clinical Development

The resulting evidence contributes to the overall package supporting human clinical research.

The exact sequence and requirements vary between development programmes, therapeutic modalities and regulatory jurisdictions.

The Role of Preclinical Respiratory Research in Drug Development

IND-enabling respiratory studies represent an important transition point in the development of respiratory therapeutics.

By combining respiratory disease models, pharmacology, pharmacokinetics, pharmacodynamics, biomarkers and safety assessment, researchers can develop a more complete understanding of a candidate before clinical testing.

For pharmaceutical and biotechnology companies developing treatments for asthma, COPD, pulmonary fibrosis, acute lung injury, respiratory infections and other pulmonary diseases, appropriately designed preclinical respiratory studies can provide important evidence for development decisions.

A specialist respiratory research programme can also help connect early pharmacology with later translational objectives, creating a more coherent path from respiratory drug discovery through preclinical development and towards clinical research.

The most effective IND-enabling respiratory studies are therefore not simply a collection of individual experiments. They are part of an integrated respiratory drug development strategy designed to understand mechanism, efficacy, exposure, biomarkers, pharmacology and safety before a candidate progresses into human studies.

IND-Enabling Respiratory Studies: A Guide to Preclinical Respiratory Drug Development